Faculty profile
Jeffrey Leyton
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Université de Sherbrooke directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $581,400
Journey to the Center of the Cell: Reprogramming intracellular transport to the nucleus enhances HER2+ tumor killing for trastuzumab conjugated to payloads active in the nucleus
CIHR · 2021 · Nominated PI
- $564,955
The great escape: Improving the activity of chemotherapeutics delivered by antibody-drug conjugates with integrated endosome escape and nuclear-directional trafficking control capabilies
CIHR · 2016 · Nominated PI
Journey to the Center of the Cell: Reprogramming intracellular transport to the nucleus enhances HER2+ tumor killing for trastuzumab conjugated to payloads active in the nucleus
Principal investigators: Leyton, Jeffrey V
Keywords: Antibody-Based Therapeutics; Nls-Based Targeted Therapeutics; Nuclear Localization Signals (Nls)
The great escape: Improving the activity of chemotherapeutics delivered by antibody-drug conjugates with integrated endosome escape and nuclear-directional trafficking control capabilies
Principal investigators: Leyton, Jeffrey V
Keywords: Antibody-Drug Conjugates; Drug Intracellular Accumulation; Nuclear Routing And Accumulation; Pet Imaging In Drug Development; Selective Endosome Escape; Targeted Chemotherapy
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.